Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
ES2545929B2 - Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme - Google Patents
[go: Go Back, main page]

ES2545929B2 - Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme - Google Patents

Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme Download PDF

Info

Publication number
ES2545929B2
ES2545929B2 ES201401058A ES201401058A ES2545929B2 ES 2545929 B2 ES2545929 B2 ES 2545929B2 ES 201401058 A ES201401058 A ES 201401058A ES 201401058 A ES201401058 A ES 201401058A ES 2545929 B2 ES2545929 B2 ES 2545929B2
Authority
ES
Spain
Prior art keywords
sod
enzyme
antibodies
antibody
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201401058A
Other languages
Spanish (es)
Other versions
ES2545929A1 (en
Inventor
Juan Antonio GARCÍA RANEA
Miguel MEDINA TORRES
Javier Alejandro GARCÍA-VILAS GARCÍA
Juan Francisco MORILLA DOMÍNGUEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Malaga
Original Assignee
Universidad de Malaga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Malaga filed Critical Universidad de Malaga
Priority to ES201401058A priority Critical patent/ES2545929B2/en
Publication of ES2545929A1 publication Critical patent/ES2545929A1/en
Application granted granted Critical
Publication of ES2545929B2 publication Critical patent/ES2545929B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de anticuerpos frente a la enzima SOD-3 para la inhibición del proceso de la angiogénesis y aplicaciones de dichos anticuerpos y de dicha enzima SOD-3. La presente invención se refiere al uso de la enzima SOD-3 como nueva diana molecular en prevención, terapia y/o tratamiento de patologías que cursan con angiogénesis, como por ejemplo degeneración macular asociada a la edad, artritis reumatoide o psoriasis; así como al uso en prevención, terapia y/o tratamiento de dichas patologías de anticuerpos que se unen, reaccionan o reconocen específicamente a SOD-3, y que modulan, preferentemente que inhiben, la actividad de dicha enzima, particularmente la actividad de SOD-3 humana.Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme. The present invention relates to the use of the SOD-3 enzyme as a new molecular target in prevention, therapy and / or treatment of pathologies that occur with angiogenesis, such as age-related macular degeneration, rheumatoid arthritis or psoriasis; as well as the use in prevention, therapy and / or treatment of said antibody pathologies that bind, react or specifically recognize SOD-3, and that modulate, preferably that inhibit, the activity of said enzyme, particularly the activity of SOD- 3 human.

Claims (6)

REIVINDICACIONES 1. Uso de un anticuerpo que se une, reacciona o reconoce específicamente a la enzima SOD-3 que inhibe su actividad en prevención, terapia y/o tratamiento de patologías que cursan con angiogénesis. 5 1. Use of an antibody that specifically binds, reacts or recognizes the SOD-3 enzyme that inhibits its activity in prevention, therapy and / or treatment of pathologies that occur with angiogenesis. 5 2. Uso según la reivindicación anterior caracterizado por que el anticuerpo se une, reacciona o reconoce específicamente a la enzima SOD-3 humana. 2. Use according to the preceding claim characterized in that the antibody binds, reacts or specifically recognizes the human SOD-3 enzyme. 3. Uso según la reivindicación anterior caracterizado por que el anticuerpo se une, reacciona o reconoce específicamente el péptido WTGEDSAEPNSDSAEWIRD (SEQ ID NO:1), correspondiente a los aminoácidos 19-37 aminoterminales. 10 3. Use according to the preceding claim characterized in that the antibody specifically binds, reacts or recognizes the WTGEDSAEPNSDSAEWIRD peptide (SEQ ID NO: 1), corresponding to amino-terminal amino acids 19-37. 10 4. Uso según la reivindicación anterior caracterizado por que el anticuerpo es isotipo inmunoglobulina G. 4. Use according to the preceding claim characterized in that the antibody is immunoglobulin G isotype. 5. Uso según la reivindicación anterior caracterizado por que el anticuerpo es policlonal. 5. Use according to the preceding claim characterized in that the antibody is polyclonal. 6. Uso según la reivindicación anterior caracterizado por que el anticuerpo se ha producido en conejo. 15 6. Use according to the preceding claim characterized in that the antibody has been produced in rabbit. fifteen
ES201401058A 2014-12-23 2014-12-23 Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme Active ES2545929B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201401058A ES2545929B2 (en) 2014-12-23 2014-12-23 Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201401058A ES2545929B2 (en) 2014-12-23 2014-12-23 Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme

Publications (2)

Publication Number Publication Date
ES2545929A1 ES2545929A1 (en) 2015-09-16
ES2545929B2 true ES2545929B2 (en) 2016-07-15

Family

ID=54072609

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201401058A Active ES2545929B2 (en) 2014-12-23 2014-12-23 Use of antibodies against the SOD-3 enzyme for the inhibition of the angiogenesis process and applications of said antibodies and said SOD-3 enzyme

Country Status (1)

Country Link
ES (1) ES2545929B2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115039A1 (en) * 2007-03-22 2008-09-25 Industry Academic Cooperation Foundation, The Catholic University Of Korea Novel use of ec-sod and method for preparing thereof

Also Published As

Publication number Publication date
ES2545929A1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
MX2021011167A (en) HUMANIZED ANTIBODIES AGAINST HUMAN DIFFERENTIATION GROUP 19 (CD19) AND METHODS OF USE.
AR101846A1 (en) ANTI-CLL-1 ANTIBODIES AND IMMUNOCATE PLAYERS
PE20181363A1 (en) OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES
AR110321A1 (en) ANTITAU ANTIBODIES AND METHODS OF USE
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
PE20170665A1 (en) HUMANIZED ANTI-TAU ANTIBODIES
BR112022009317A2 (en) BIPARATOPIC CD73 ANTIBODIES
BR112018016697A2 (en) coated, chimeric or humanized antibody, pharmaceutical composition, and method of treatment.
PE20190737A1 (en) ANTI-CD27 ANTIBODIES
PE20181336A1 (en) ANTIBODIES THAT BIND INTERLEUKIN 8 (IL-8) AND ITS USES
PE20241514A1 (en) HUMANIZED ANTIBODY FOR TREATING OR PREVENTING COGNITIVE DISORDERS, PROCESS FOR PRODUCING IT, AND AGENT FOR TREATING OR PREVENTING COGNITIVE DISORDERS USING IT
CR20150466A (en) PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE
PE20190261A1 (en) ANTIBODIES THAT RECOGNIZE TAU
AR096687A1 (en) ANTI-FCRH5 ANTIBODIES
JOP20220119A1 (en) Trem2 antibodies and uses thereof
ES2685424T3 (en) Anti-Jagged1 antibodies and procedures for use
BR112017009817A2 (en) anti-il-1beta antibodies and methods of use
MX2018013520A (en) Dna monoclonal antibodies targeting checkpoint molecules.
MX366359B (en) Humanized antibodies against ceacam1.
BR112017009790A2 (en) anti-ang2 antibodies and methods of use
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX388698B (en) BINDING MOLECULES, ESPECIALLY ANTIBODIES, BOUND TO L1CAM (CD171).
EA201790816A1 (en) ANTIBODIES THAT ARE ASSOCIATED WITH CCR6 AND APPLICATION OPTIONS FOR THE INDICATED ANTIBODIES
BR112013024923A2 (en) new anti-human il-23 receptor antibody
MX2018012410A (en) METHODS TO TREAT INFLAMMATORY DISEASES.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2545929

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20160715